Information of abbreviation data set (5).docx

The efficacy of nefopam, a non-opioid, non-steroidal, central acting drug, for cancer pain remains unclear. We evaluated the analgesic efficacy of nefopam for cancer pain. Patients with moderate to severe cancer pain (n=40) were randomly divided into two groups. The nefopam group (n=20) received three 20 mg doses of nefopam every 8 hours. The placebo group (n=20) received normal saline. Intravenous patient-controlled analgesia with morphine was given for breakthrough pain for 48 hours. The primary outcome was significant pain reduction. Secondary outcomes were morphine consumption over 48 hours and incidence of side effects.<br>Article relating to this data published on F1000Research: DOI 10.12688/f1000research.23455.1.<br>奈福泮（nefopam）是一种非阿片类、非甾体类中枢作用药物，其用于癌症疼痛的疗效仍不明确。本研究评估了奈福泮治疗癌症疼痛的镇痛疗效。 将40例中度至重度癌症疼痛患者随机分为两组。奈福泮组（n=20）每8小时给予20 mg奈福泮，共给药3次；安慰剂组（n=20）给予生理盐水。 针对癌性爆发痛，予以吗啡静脉患者自控镇痛（intravenous patient-controlled analgesia, IV-PCA），干预时长为48小时。 本研究的主要结局指标为疼痛显著缓解，次要结局指标为48小时内吗啡消耗量及不良反应发生率。 本数据集相关研究论文已发表于F1000Research：DOI 10.12688/f1000research.23455.1。